Therapeutic indications
Eylea is indicated for treatment in adults
• neovascular (wet) age-related macular degeneration (AMD),
• visual impairment due to macular edema due to retinal vein occlusion (branch of the PVO or central PVO),
• visual impairment due to diabetic macular edema (DME),
• Visual impairment due to myopic choroidal neovascularization (myopic CNV)
Eylea is intended for intravitreal injections only.
Eylea should only be prescribed by a qualified healthcare professional experienced in intravitreal injections.
Dosage
wet AMD
The recommended dose of Eylea is 2 mg of aflibercept, which is equivalent to 0.05 ml.
Eylea treatment begins with one injection per month in three consecutive doses. Then the treatment interval increases to two months.
In the physician’s opinion regarding visual and/or anatomical results, the treatment interval may be maintained at two months or further extended using a “treat and extend” dosing regimen in which the intervals between injections are increased in increments of 2 or 4 weeks to maintain stable visual and/or anatomical results. If visual and/or anatomical results worsen, the treatment interval should be reduced accordingly.
There is no need for monitoring between injections. At the discretion of the physician, the schedule of monitoring visits may be more frequent than injection visits.
4.3 Contraindications
Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1.
Active or suspected ocular or periocular infection.
Active severe intraocular inflammation.
